VIVUS Announces Positive Outcome of European Procedure to Extend QSIVA® (Phentermine/Topiramate MR) to Adolescents with Obesity
Financial Post · · g2759794
— Landmark European approval will grant young patients and families an evidence-based therapy alongside lifestyle interventions AMSTERDAM, Oct. 19, 2026 (GLOBE NEWSWIRE) — VIVUS BV, a subsidiary of VIVUS LLC, a biopharmaceutical company committed to the development and commercialization of innovative therapies that focus on advancing treatments for patients with serious unmet medical needs and […]
AMSTERDAM, Oct. 19, 2026 (GLOBE NEWSWIRE) -- VIVUS BV, a subsidiary of VIVUS LLC, a biopharmaceutical company committed to the development and commercialization of innovative therapies that focus on advancing treatments for patients with serious unmet medical needs and life-limiting diseases, today announced the positive conclusion of the European variation procedure to extend the indication of QSIVA ® (phentermine/topiramate MR) to adolescents aged 12 years and older with obesity. The national medicines agencies of the 17 countries in the procedure will now issue national decisions, expected in as little as 30 days. QSIVA ® is already approved in these countries for weight management in adults: Croatia, Czechia, Denmark, Finland, Greece * , Hungary, Iceland, Ireland, Lithuania, Malta, Norway, Poland, Portugal, Romania, Slovakia, Slovenia and Sweden. Read More